One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Evogene Ltd.
EVGN · NCM · Healthcare · Biotechnology
Current price
$0.48
52-week range
$0.37 - $1.50
Market cap
$7.59M
Balance sheet
Healthy
-89.39x Concerning
Net cash $7.21M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Evogene Ltd.
Evogene is a research company that uses artificial intelligence to design new products for farming, human health, and industrial uses. They create things like improved seeds, medical cannabis, and potential new medicines for heart and inflammatory diseases. The company's goal is to make money by partnering with larger firms to bring these discoveries to the public, so its success depends on its technology creating valuable breakthroughs.
How the company got here
Founded in 1999 and headquartered in Israel, Evogene started by using computational biology, which is like using powerful computers to understand living things, to improve seeds for agriculture. Over the years, it expanded this computer-based approach to discover and design tiny molecules for various uses. A key turning point was the development of its AI (Artificial Intelligence) technology, now called ChemPass AI, which helps invent new chemicals for medicine and farming much faster. Recently, the company has sharpened its focus on just two main areas, pharmaceuticals and agriculture, and has sold off or closed down other parts of its business to concentrate its efforts.
What it actually does
Evogene is a technology company that uses powerful computers and artificial intelligence (AI) to invent new, tiny molecules. Think of it like a high-tech discovery engine for the building blocks of future products. Instead of mixing chemicals in a lab through trial and error, Evogene's AI platform, called ChemPass AI, designs and tests new molecules on a computer first. This process aims to find effective and safe ingredients for new medicines to treat diseases and new crop protection products, like weed or fungus killers, for farmers. The company doesn't typically make the final products you'd buy in a store; instead, it partners with large pharmaceutical and agricultural companies who then develop and sell those products.
Agriculture
This part of the company, which includes a subsidiary named AgPlenus, uses the ChemPass AI platform to invent new chemicals for farming. The main goal is to create next-generation crop protection products, such as herbicides (weed killers) and fungicides (fungus killers), that are more effective and sustainable. Farmers and large agricultural companies are the customers, paying for these new solutions to protect their crops from pests and diseases that have become resistant to older chemicals. This segment is a core focus for Evogene and involves collaborations with major global agriculture companies like Bayer and Corteva.
Human Health
In this segment, Evogene uses its ChemPass AI engine to design new small molecules that could become future medicines. The company partners with biotechnology companies and research institutions to discover potential treatments for various diseases, such as inflammatory bowel disease (IBD) and cancer. These partners pay Evogene for its discovery work and then take the most promising molecules through the long process of lab testing and clinical trials (testing in humans) needed to create a new drug. This is a major area of focus for the company, representing a significant part of its strategy.
Industrial Applications
This smaller segment has historically included the development and sale of castor bean seeds for industrial uses, like making biofuels and plastics. The customers are businesses in the industrial and energy sectors that need a sustainable source of castor oil. While this segment has generated revenue (money earned from sales) for the company, Evogene's recent strategic shift has focused resources more heavily on its Agriculture and Human Health divisions.
What management is betting on now
Management is making a concentrated bet on its proprietary (meaning they own it) technology called the ChemPass AI engine. They have streamlined the company to focus almost exclusively on using this AI to design small molecules for two key markets: human health and agriculture. The strategy is to be a lean, technology-focused company that partners with larger firms to bring final products to market, which is a capital-efficient (a way to operate without needing huge amounts of money) business model. By divesting (selling off) non-core assets and reducing operating expenses (the day-to-day costs of running a business), they are aiming for sustainable, long-term growth driven by their AI-powered discovery platform.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $0.48
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.2M - more cash than debt. Interest coverage -89.4x.
Net debt
$-7.21M
Interest coverage
-89.39x
Evogene Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
EVGN
BASELINE
Evogene Ltd.
Total debt $2.10M Interest coverage -89.39x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage -499.75x Neither company has much profit cushion over interest right now.
Total debt $1.75M Interest coverage -7.85x Neither company has much profit cushion over interest right now.
What you should know
The case for and against EVGN
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -182.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.60x
P/B
-1.98x
P/S
4.58x
EV/EBITDA
-0.60x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-67.6%
Operating margin
-738.6%
Net margin
0.0%
ROE
-182.7%
ROA
-37.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.36x
Current ratio
3.57x
Quick ratio
3.52x
Total debt
$2.10M
Total cash
$9.32M
Growth
How the business has been compounding
Revenue TTM
$1.66M
Revenue 5Y CAGR
32.0%
EPS TTM
-1.75
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-13.50M
Free CF TTM
$-13.64M
FCF margin
-823.0%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—